Medical technology company PAVmed has signed a nonbinding letter of intent with Durham, N.C.-based Duke University to license a multimodality endoscopic probe designed to detect and treat advanced esophageal precancer.
The device combines angle-resolved low coherence interferometry with optical coherence tomography, offering the potential for real-time detection of dysplasia during endoscopy, in contrast to traditional biopsies, according to an Aug. 26 system news release.
“This groundbreaking technology has the potential to fundamentally transform how we diagnose and treat esophageal precancer, while simultaneously improving patient outcomes, procedural efficiency and healthcare resource utilization,” Nicholas Shaheen, MD, of Chapel Hill-based UNC Health, said in the release.
PAVmed plans to develop the technology through a newly formed subsidiary under its shared services model. The definitive license agreement has not yet been finalized.
